-

Cracking the code: researchers unravel how mutant protein drives cancer growth

This article featured in Illuminate Newsletter Autumn ‘24
Key Researchers
Portrait of Gemma Kelly
Laboratory Head
Gemma Kelly, Andreas Strasser and Zilu Wang are photographed standing outside WEHI's main entrance

WEHI researchers have solved a mystery about the most important driver of cancer development – a mutant protein found in half of all cancers – and how it contributes to tumour growth.

The p53 protein is a tumour suppressor that plays a crucial role in preventing the formation of cancerous cells. But when it mutates and becomes defective in cells, the protein can significantly boost a person’s risk of cancer development.

In a first, researchers have revealed what behaviours of the mutated protein are critical for fuelling tumour growth – a discovery that could offer new directions for the development of treatment options.

At a glance
Findings show, for the first time, what traits of the mutant p53 protein are critical for driving cancer growth.
Mutations of this protein are considered to be the biggest driver of cancer development and are found in half of all human cancers around the globe.
The discovery will help rethink ways to therapeutically treat cancers with p53 mutations, leading to new and improved cancer treatments in future.

When it works properly, the p53 protein serves as a powerful defence mechanism against cancer development by ensuring that cells with compromised DNA either get repaired or removed from our body.

Mutations to this protein can be triggered by a variety of environmental factors – such as exposure to UV radiation – if the body’s cell division process goes awry, or if they are genetically inherited.

These abnormalities can lead to a dysfunctional protein that has lost the crucial ability to regulate cellular responses that prevent tumour development and growth. This is known as loss-of-function.

Additionally, some researchers believe these mutations can also lead to a supercharged protein that helps cancerous cells survive and proliferate, known as gain-of-function.

In a new study, published in Cancer Discovery, researchers from WEHI and Trento University (Italy) have answered an age-old question by proving which function helps mutant p53 fuel tumour growth.

Associate Professor Gemma Kelly, a co-corresponding author of the paper, said understanding how exactly these mutations contribute to cancer is critical to understanding how to treat patients bearing cancers with the dysfunctional proteins.

“Our study has provided the first evidence to show that it is actually the loss-of-function that impacts cancer growth. We found no evidence of gain-of-function contributing to cancer growth,” Assoc Prof Kelly, a Laboratory Head in WEHI’s Blood Cells and Blood Cancer Division, said.

“This is significant because until now, there was not much evidence available to properly show whether it is the protein’s loss or gain-of-function that spurs cancer growth.

“If you look at all cancers of humanity, about 50% of them have a mutation in p53. Specific cancers like those of the pancreas, lung and breast, commonly have defects in these proteins.”

“Our findings have transformed our understanding of these mutations, which help rethink how they can be targeted in the development of new cancer treatments.”
Associate Professor Gemma Kelly

Unprecedented data exploration

The study utilised the powerful gene editing tool CRISPR to remove 12 different, mutated versions of the protein with reported gain-of-function effects. Researchers found there was no change to the behaviour of cancer cells, in growth or response to chemotherapy.

Leveraging a significant collaboration with The University of Trento (Italy), the research team was also able to restore p53’s normal functions that were lost when the protein mutated. They found this reduced cancer growth, in pre-clinical models.

First author Dr Zilu Wang was able to use these models and data from the DepMap database in an in-depth way that had never been done before to consolidate the findings.

“Having these tools at my disposal allowed me to assess 157 different p53 mutations,” Dr Wang said.

“The mutations I looked at basically account for at least 90% of human cancers with defects in p53, which will provide crucial insight when informing the development of new anti-cancer strategies.”

Future treatments

Co-corresponding author, Professor Andreas Strasser, said the findings could prevent hundreds of millions of dollars being wasted on developing ineffective drugs.

“There is research underway that is working towards finding the first therapeutics to target gain-of-function traits,” Prof Strasser, Head of WEHI’s Blood Cells and Blood Cancer Division, said.

“Our findings indicate there is no further merit in this therapeutic avenue and the focus needs to shift to restoring the mutant protein’s lost function and normal tumour suppressor ability.”

This work was supported by the Victorian Cancer Agency, Cancer Council Victoria, the National Health and Medical Research Council, the Leukaemia Foundation Australia, the Leukaemia and Lymphoma Society, the Giovanni Armenise-Harvard Foundation, the estate of Anthony (Toni) Redstone OAM, The Craig Perkins Cancer Research Foundation, The Harry Secomb Trust and the Dyson Bequest, the Australian Government and the Victorian State Government.

Banner image: Assoc Prof Gemma Kelly, Prof Andreas Strasser and Dr Zilu Wang at WEHI.

First published on 28 November 2023
This article featured in Illuminate Newsletter Autumn ‘24
Reference
Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival and metastasis of a broad range of cancer cells
Journal
Cancer Discov
DOI
10.1158/2159-8290.CD-23-0402
Full details
WEHI Authors
Portrait of Gemma Kelly
Laboratory Head
Senior Research Officer
Research Officer
Bianco Capaldo profile
Research Officer
Dr Michelle Palmieri
CDT Coordinator
Dr Yumiko Hirokawa
Dr Yumiko Hirokawa
Lin Tai
Honorary Research Associate
Daniel Simpson
Daniel Simpson
Catherine Chang
Research Assistant
Elizabeth Lieschke
Elizabeth Lieschke
Senior Research Officer
PhD Student
Chris Riffkin
Research Assistant
Laboratory Head
Senior Research Officer
Head, Bioinformatics Support Facility
Division Head
Photo of Jane Visvader in her office
Division Head
Photo of Oliver Sieber with a window in the background
Laboratory Head
Prof Marco Herold
Prof Marco Herold
Support us

Together we can create a brighter future

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Sign up to our quarterly newsletter Illuminate

Find out about recent discoveries, community supporters and more.

Illuminate Autumn 2024
View the current issue